Anne E. Lykkesfeldt

4.3k total citations
111 papers, 3.5k citations indexed

About

Anne E. Lykkesfeldt is a scholar working on Genetics, Molecular Biology and Oncology. According to data from OpenAlex, Anne E. Lykkesfeldt has authored 111 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Genetics, 55 papers in Molecular Biology and 47 papers in Oncology. Recurrent topics in Anne E. Lykkesfeldt's work include Estrogen and related hormone effects (66 papers), HER2/EGFR in Cancer Research (29 papers) and Monoclonal and Polyclonal Antibodies Research (11 papers). Anne E. Lykkesfeldt is often cited by papers focused on Estrogen and related hormone effects (66 papers), HER2/EGFR in Cancer Research (29 papers) and Monoclonal and Polyclonal Antibodies Research (11 papers). Anne E. Lykkesfeldt collaborates with scholars based in Denmark, United States and Sweden. Anne E. Lykkesfeldt's co-authors include Per Briand, Christina W. Yde, Anne‐Vibeke Lænkholm, Jan Stenvang, S. S. Larsen, Thomas Frogne, Mogens Winkel Madsen, Birgitte Rasmussen, Katrine L. Henriksen and Bent Ejlertsen and has published in prestigious journals such as The Journal of Cell Biology, PLoS ONE and Cancer Research.

In The Last Decade

Anne E. Lykkesfeldt

111 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anne E. Lykkesfeldt Denmark 39 1.8k 1.4k 1.4k 803 408 111 3.5k
Stephen Hiscox United Kingdom 36 2.1k 1.1× 1.4k 1.0× 472 0.3× 629 0.8× 353 0.9× 93 3.8k
Dorraya El‐Ashry United States 31 1.7k 0.9× 1.7k 1.2× 789 0.6× 972 1.2× 275 0.7× 52 3.1k
Alan E. Wakeling United Kingdom 26 1.5k 0.8× 1.2k 0.9× 1.6k 1.2× 458 0.6× 412 1.0× 44 3.1k
Louise R. Howe United States 28 2.5k 1.3× 1.1k 0.8× 959 0.7× 702 0.9× 212 0.5× 37 4.4k
R A McClelland United Kingdom 30 982 0.5× 1.3k 0.9× 1.1k 0.8× 505 0.6× 244 0.6× 45 2.5k
Lesley‐Ann Martin United Kingdom 33 1.8k 1.0× 1.9k 1.3× 1.2k 0.9× 1.3k 1.6× 1.2k 2.9× 80 3.9k
Shixia Huang United States 30 2.4k 1.3× 1.3k 0.9× 481 0.3× 651 0.8× 372 0.9× 70 3.7k
Rui‐An Wang United States 29 2.2k 1.2× 1.1k 0.8× 720 0.5× 604 0.8× 201 0.5× 56 3.1k
J. Chuck Harrell United States 35 1.9k 1.0× 1.8k 1.2× 668 0.5× 1.1k 1.4× 467 1.1× 78 3.6k
Ching‐yi Chang United States 37 2.5k 1.4× 785 0.5× 1.8k 1.3× 1.2k 1.5× 710 1.7× 69 4.8k

Countries citing papers authored by Anne E. Lykkesfeldt

Since Specialization
Citations

This map shows the geographic impact of Anne E. Lykkesfeldt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne E. Lykkesfeldt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne E. Lykkesfeldt more than expected).

Fields of papers citing papers by Anne E. Lykkesfeldt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne E. Lykkesfeldt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne E. Lykkesfeldt. The network helps show where Anne E. Lykkesfeldt may publish in the future.

Co-authorship network of co-authors of Anne E. Lykkesfeldt

This figure shows the co-authorship network connecting the top 25 collaborators of Anne E. Lykkesfeldt. A scholar is included among the top collaborators of Anne E. Lykkesfeldt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne E. Lykkesfeldt. Anne E. Lykkesfeldt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eliáš, Daniel, Carla L. Alves, Martin V. Bennetzen, et al.. (2021). MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. npj Breast Cancer. 7(1). 2–2. 11 indexed citations
2.
Lykkesfeldt, Anne E., Maj‐Britt Jensen, Bent Ejlertsen, et al.. (2017). Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. Acta Oncologica. 57(1). 67–73. 16 indexed citations
3.
Persson, C., Julhash U. Kazi, Lars Rönnstrand, et al.. (2016). HIF2α contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells. Oncotarget. 7(10). 11238–11250. 19 indexed citations
4.
Alves, Carla L., Daniel Eliáš, Maria Lyng, et al.. (2016). High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer. Clinical Cancer Research. 22(22). 5514–5526. 53 indexed citations
5.
Lænkholm, Anne‐Vibeke, et al.. (2015). Src Drives Growth of Antiestrogen Resistant Breast Cancer Cell Lines and Is a Marker for Reduced Benefit of Tamoxifen Treatment. PLoS ONE. 10(2). e0118346–e0118346. 24 indexed citations
6.
PEDERSEN, ASTRID M., et al.. (2015). Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells. Breast Cancer Research and Treatment. 149(3). 715–726. 38 indexed citations
7.
Kirkegaard, Tove, Christina W. Yde, Marie Kveiborg, & Anne E. Lykkesfeldt. (2014). The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines. International Journal of Oncology. 45(1). 393–400. 8 indexed citations
8.
9.
Thrane, Susan, Anne E. Lykkesfeldt, Mathilde Skaarup Larsen, Boe Sandahl Sørensen, & Christina W. Yde. (2013). Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling. Breast Cancer Research and Treatment. 139(1). 71–80. 61 indexed citations
10.
Larsen, Mathilde Skaarup, Karsten Bjerre, Anita Giobbie‐Hurder, et al.. (2012). Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy. Acta Oncologica. 51(6). 781–789. 18 indexed citations
11.
Lundqvist, Johan, et al.. (2012). Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter—a new regulatory pathway for aromatase. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1833(1). 40–47. 24 indexed citations
12.
Balslev, Eva, Anne E. Lykkesfeldt, Niels Kroman, et al.. (2011). Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer. Breast Cancer Research and Treatment. 128(1). 165–170. 3 indexed citations
13.
14.
Yde, Christina W., Mathias P. Clausen, Martin V. Bennetzen, et al.. (2009). The antipsychotic drug chlorpromazine enhances the cytotoxic effect of tamoxifen in tamoxifen-sensitive and tamoxifen-resistant human breast cancer cells. Anti-Cancer Drugs. 20(8). 723–735. 60 indexed citations
15.
Henriksen, Katrine L., et al.. (2008). Development of new predictive markers for endocrine therapy and resistance in breast cancer. Acta Oncologica. 47(4). 795–801. 2 indexed citations
16.
Lykkesfeldt, Anne E., et al.. (2005). Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. The Journal of Steroid Biochemistry and Molecular Biology. 93(1). 25–34. 70 indexed citations
17.
Crémoux, Patricia de, et al.. (2003). Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens.. Endocrine Related Cancer. 10(3). 409–418. 38 indexed citations
18.
Larsen, S. S., Mikala Egeblad, Marja Jäättelä, & Anne E. Lykkesfeldt. (1999). Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family. Breast Cancer Research and Treatment. 58(1). 41–56. 41 indexed citations
19.
Laursen, Inga & Anne E. Lykkesfeldt. (1992). Purification and characterization of an α1-antichymotrypsin-like 66 kDa protein from the human breast cancer cell line, MCF-7. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology. 1121(1-2). 119–129. 16 indexed citations
20.
Lykkesfeldt, Gert, Anne E. Lykkesfeldt, & N. E. Skakkeb�k. (1984). Steroid sulphatase in man: A non inactivated X-locus with partial gene dosage compensation. Human Genetics. 65(4). 355–357. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephen Hiscox Breakdown of academic impact, for papers by Dorraya El‐Ashry Breakdown of academic impact, for papers by Alan E. Wakeling Breakdown of academic impact, for papers by Louise R. Howe Breakdown of academic impact, for papers by R A McClelland Breakdown of academic impact, for papers by Lesley‐Ann Martin Breakdown of academic impact, for papers by Shixia Huang Breakdown of academic impact, for papers by Rui‐An Wang Breakdown of academic impact, for papers by J. Chuck Harrell Breakdown of academic impact, for papers by Ching‐yi Chang
Rankless by CCL
2026